Conduit Pharmaceuticals Stock Forward View - Double Exponential Smoothing
| CDT Stock | 0.57 -0.06 -9.52% |
Predicting Conduit Pharmaceuticals' future price is a multi-variable problem that combines fundamental signals, technical structure, and market sentiment. This module focuses specifically on the hype and news dimension of that forecast.
At present, the relative strength indicator for Conduit Pharmaceuticals registers 30, placing the security in oversold territory. Values below 30 typically indicate extended downward momentum relative to recent price action.Momentum
Sell Stretched
Oversold | Overbought |
This section relates Conduit Pharmaceuticals headline activity to recent price behavior and peer context.
The Double Exponential Smoothing forecasted value of Conduit Pharmaceuticals on the next trading day is expected to be 0.55 with a mean absolute deviation of 0.06 and the sum of the absolute errors of 3.46.Conduit Pharmaceuticals after-hype prediction price | $ 0.57 |
Hype signals are presented as complementary context to forecasting, technicals, analyst estimates, earnings, and momentum.
Use Historical Fundamental Analysis of Conduit Pharmaceuticals to cross-verify projections for Conduit Pharmaceuticals. The historical view provides additional context.Conduit Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Conduit price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Conduit using various technical indicators. When you analyze Conduit charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Conduit Pharmaceuticals Double Exponential Smoothing Price Forecast For the 13th of March 2026
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Conduit Pharmaceuticals on the next trading day is expected to be 0.55 with a mean absolute deviation of 0.06 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 3.46 .Please note that although there have been many attempts to predict Conduit Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Conduit Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Conduit Pharmaceuticals Stock Forecast Pattern
| Backtest Conduit Pharmaceuticals | Conduit Pharmaceuticals Price Prediction | Research Analysis |
Conduit Pharmaceuticals Forecasted Value
This next-day forecast for Conduit Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Conduit Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Conduit Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0122 |
| MAD | Mean absolute deviation | 0.0577 |
| MAPE | Mean absolute percentage error | 0.0514 |
| SAE | Sum of the absolute errors | 3.4592 |
The concept of mean reversion suggests that Conduit Pharmaceuticals' price will eventually return toward its long-run average. High prices may deter value investors, while unusually low prices often attract buyers who anticipate a recovery.
Conduit Pharmaceuticals After-Hype Price Density Analysis
The price distribution graph for Conduit Pharmaceuticals visualizes the statistical uncertainty around our prediction model's output. Investors should interpret the full distribution of Conduit Pharmaceuticals' outcomes, not just the central tendency, when making decisions.
Next price density |
| Expected price to next headline |
Conduit Pharmaceuticals Estimiated After-Hype Price Volatility
The downside and upside margins for Conduit Pharmaceuticals after major news events are estimated from historical precedent. Conduit Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.03 and 7.44, respectively. This approach captures the empirical distribution of Conduit Pharmaceuticals' short-term price reactions without assuming any particular model of future behavior.
Current Value
The after-hype framework applied to Conduit Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Conduit Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Conduit Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Conduit Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Conduit Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.61 | 6.92 | 0.03 | 0.07 | 7 Events | 5 Events | In 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.57 | 0.57 | 0.00 |
|
Conduit Pharmaceuticals Hype Timeline
On the 12th of March 2026 Conduit Pharmaceuticals is traded for 0.57. The company has historical hype elasticity of -0.03, and average elasticity to hype of competition of -0.07. Conduit is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -1.61%. %. The volatility of related hype on Conduit Pharmaceuticals is about 15043.48%, with the expected price after the next announcement by competition of 0.50. About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.54. Some equities with similar Price to Book (P/B) outperform the market in the long run. Conduit Pharmaceuticals recorded a loss per share of 179.34. The company had not issued any dividends in recent years. The firm completed a 1:8 stock split on 13th of October 2025. Considering the 90-day investment horizon the next forecasted press release will be in 7 days. Use Historical Fundamental Analysis of Conduit Pharmaceuticals to cross-verify projections for Conduit Pharmaceuticals. The historical view provides additional context.Conduit Pharmaceuticals Related Hype Analysis
The relationship between Conduit Pharmaceuticals and its sector peers means that news affecting one company often reverberates across Conduit Pharmaceuticals' competitive landscape. Tracking peer hype helps investors anticipate Conduit Pharmaceuticals's likely short-term price behavior.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| HEPA | Hepion Pharmaceuticals | 0.04 | 9 per month | 0.00 | -0.44 | 13.95 | -25.00 | 78.13 | |
| XAGE | Longevity Health Holdings | 0.02 | 7 per month | 0.00 | -0.02 | 16.67 | -11.11 | 46.18 | |
| ZVSA | ZyVersa Therapeutics | 0.01 | 6 per month | 6.14 | 0.14 | 17.65 | -11.54 | 86.14 | |
| COCH | Envoy Medical | -0.06 | 9 per month | 5.47 | 0.03 | 10.29 | -9.23 | 90.44 | |
| WORX | Scworx Corp | 0.01 | 6 per month | 0.00 | -0.01 | 15.38 | -16.67 | 79.94 | |
| LIXT | Lixte Biotechnology Holdings | -0.17 | 9 per month | 0.00 | -0.06 | 10.20 | -6.85 | 22.37 | |
| NIVF | NewGenIvf Group Limited | -0.16 | 5 per month | 0.00 | -0.27 | 12.36 | -20.45 | 53.65 | |
| PTPI | Petros Pharmaceuticals | 0.00 | 0 per month | 0.00 | -0.04 | 14.29 | -12.50 | 45.83 | |
| CCM | Concord Medical Services | -0.03 | 10 per month | 4.71 | 0.04 | 12.41 | -7.83 | 25.36 | |
| ENVB | Enveric Biosciences | -0.12 | 9 per month | 0.00 | -0.07 | 9.81 | -11.42 | 121.83 |
Other Forecasting Options for Conduit Pharmaceuticals
Whether a novice or experienced investor, anyone considering Conduit needs to understand the dynamics of Conduit Pharmaceuticals' price movement. Price charts for Conduit Stock contain a significant amount of noise that can distort investment decisions.Conduit Pharmaceuticals Related Equities
The following equities are related to Conduit Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Conduit Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Conduit Pharmaceuticals Market Strength Events
Analyzing market strength indicators for Conduit Pharmaceuticals enables investors to understand how the stock performs relative to overall market momentum. These indicators are valuable tools for identifying when to enter or exit positions in Conduit Pharmaceuticals.
Conduit Pharmaceuticals Risk Indicators
Identifying and analyzing Conduit Pharmaceuticals' key risk indicators is a foundational step in projecting how its price may evolve. This process helps investors quantify the risk associated with Conduit Pharmaceuticals' and decide how to manage it.
| Mean Deviation | 5.16 | |||
| Standard Deviation | 7.11 | |||
| Variance | 50.61 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Conduit Pharmaceuticals
Coverage intensity for Conduit Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Conduit Pharmaceuticals Short Properties
Short sentiment tied to Conduit Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 40.2 M | |
| Dividends Paid | 8 M | |
| Cash And Short Term Investments | 389.9 M | |
| Shares Float | 1.4 M |
Additional Tools for Conduit Stock Analysis
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |